Establishment Labs Holdings (ESTA) Stock Analysis & Winston Score

Establishment Labs Holdings makes breast implants and body contouring medical devices. Its main product line is called Motiva, which uses advanced silicone technology designed to feel more natural and reduce complications compared to older implants. The company sells primarily to plastic surgeons and hospitals, serving patients seeking cosmetic or reconstructive breast surgery. The company earns revenue by selling its devices directly to surgeons and clinics, with a focus on international markets — Europe, Latin America, and parts of Asia — where it has built a strong presence. It is working to expand into the large US market, where its Motiva implants received FDA approval in 2024, opening a significant new growth opportunity. With a gross margin above 70%, the underlying product economics are strong, but the company is still spending heavily to grow, which explains its negative operating margin. The key risk is whether it can gain meaningful US market share against established competitors like Allergan and Sientra.